NicOx S.A.
Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve eye health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in P… Read more
NicOx S.A. (ALCOX) - Total Liabilities
Latest total liabilities as of June 2025: €19.39 Million EUR
Based on the latest financial reports, NicOx S.A. (ALCOX) has total liabilities worth €19.39 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
NicOx S.A. - Total Liabilities Trend (2019–2024)
This chart illustrates how NicOx S.A.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
NicOx S.A. Competitors by Total Liabilities
The table below lists competitors of NicOx S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tier1 Technology S.A.
MC:TR1
|
Spain | €6.52 Million |
|
AB Traction
ST:TRAC-B
|
Sweden | Skr3.50 Million |
|
PVP Ventures Limited
NSE:PVP
|
India | ₹3.20 Billion |
|
EcoFirst Consolidated Bhd
KLSE:3557
|
Malaysia | RM463.23 Million |
|
JMC Electronics Co Ltd
TW:6552
|
Taiwan | NT$1.25 Billion |
|
Ekso Bionics Holdings Inc
NASDAQ:EKSO
|
USA | $11.08 Million |
|
Broncus Holding Corporation
PINK:BRNHF
|
USA | $5.29 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down NicOx S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 4.48 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -4.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NicOx S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NicOx S.A. (2019–2024)
The table below shows the annual total liabilities of NicOx S.A. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €21.01 Million | -33.45% |
| 2023-12-31 | €31.57 Million | -5.91% |
| 2022-12-31 | €33.55 Million | -14.10% |
| 2021-12-31 | €39.06 Million | -5.73% |
| 2020-12-31 | €41.43 Million | +168.25% |
| 2019-12-31 | €15.45 Million | -- |